News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
306,673 Results
Type
Article (17311)
Company Profile (300)
Press Release (289056)
Multimedia
Podcasts (79)
Webinars (11)
Section
Business (83180)
Career Advice (305)
Deals (14159)
Drug Delivery (50)
Drug Development (51822)
Employer Resources (59)
FDA (6187)
Job Trends (5621)
News (151160)
Policy (11048)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (1034)
Accelerated approval (19)
Adcomms (14)
Allergies (87)
Alliances (22459)
ALS (126)
Alzheimer's disease (1106)
Antibody-drug conjugate (ADC) (244)
Approvals (6376)
Artificial intelligence (289)
Autoimmune disease (116)
Automation (11)
Bankruptcy (119)
Best Places to Work (4892)
BIOSECURE Act (9)
Biosimilars (115)
Biotechnology (231)
Bladder cancer (108)
Brain cancer (46)
Breast cancer (361)
Cancer (3216)
Cardiovascular disease (262)
Career advice (271)
Career pathing (10)
CAR-T (220)
CDC (6)
Cell therapy (577)
Cervical cancer (15)
Clinical research (44507)
Collaboration (1181)
Company closure (2)
Compensation (599)
Complete response letters (40)
COVID-19 (1264)
CRISPR (87)
C-suite (568)
Cystic fibrosis (113)
Data (4430)
Denatured (15)
Depression (95)
Diabetes (283)
Diagnostics (1636)
Digital health (14)
Diversity (5)
Diversity, equity & inclusion (16)
Drug discovery (197)
Drug pricing (64)
Drug shortages (6)
Duchenne muscular dystrophy (219)
Earnings (33214)
Editorial (31)
Employer branding (9)
Employer resources (51)
Events (52998)
Executive appointments (628)
FDA (8005)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (1019)
Gene editing (184)
Generative AI (24)
Gene therapy (503)
GLP-1 (560)
Government (1442)
Grass and pollen (3)
Guidances (176)
Healthcare (7242)
HIV (22)
Huntington's disease (45)
IgA nephropathy (74)
Immunology and inflammation (194)
Immuno-oncology (40)
Indications (67)
Infectious disease (1390)
Inflammatory bowel disease (158)
Inflation Reduction Act (10)
Influenza (47)
Intellectual property (168)
Interviews (41)
IPO (7645)
IRA (15)
Job creations (993)
Job search strategy (230)
JPM (44)
Kidney cancer (9)
Labor market (34)
Layoffs (261)
Leadership (13)
Legal (1586)
Liver cancer (46)
Longevity (11)
Lung cancer (425)
Lymphoma (255)
Machine learning (28)
Management (14)
Manufacturing (412)
MASH (133)
Medical device (3033)
Medtech (3046)
Mergers & acquisitions (7191)
Metabolic disorders (799)
Multiple sclerosis (108)
NASH (13)
Neurodegenerative disease (236)
Neuropsychiatric disorders (70)
Neuroscience (2047)
Neurotech (1)
NextGen: Class of 2026 (2295)
Non-profit (1116)
Now hiring (31)
Obesity (369)
Opinion (145)
Ovarian cancer (134)
Pain (105)
Pancreatic cancer (162)
Parkinson's disease (233)
Partnered (16)
Patents (309)
Patient recruitment (335)
Peanut (45)
People (27390)
Pharmaceutical (44)
Pharmacy benefit managers (13)
Phase 1 (15661)
Phase 2 (20597)
Phase 3 (13175)
Pipeline (3379)
Policy (106)
Postmarket research (902)
Preclinical (6618)
Press Release (31)
Prostate cancer (155)
Psychedelics (50)
Radiopharmaceuticals (242)
Rare diseases (658)
Real estate (1613)
Recruiting (24)
Regulatory (10499)
Reports (25)
Research institute (1070)
Resumes & cover letters (46)
Rett syndrome (24)
RNA editing (21)
RSV (19)
Schizophrenia (123)
Series A (186)
Series B (139)
Service/supplier (1)
Sickle cell disease (78)
Special edition (20)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2054)
State (1)
Stomach cancer (5)
Supply chain (40)
Tariffs (24)
The Weekly (63)
Vaccines (411)
Venture capital (71)
Weight loss (208)
Women's health (31)
Worklife (3)
Date
Today (54)
Last 7 days (340)
Last 30 days (1223)
Last 365 days (18500)
2026 (1773)
2025 (18738)
2024 (21259)
2023 (23218)
2022 (31896)
2021 (32631)
2020 (26737)
2019 (17895)
2018 (13051)
2017 (14377)
2016 (12565)
2015 (15033)
2014 (10888)
2013 (7970)
2012 (8031)
2011 (8159)
2010 (7855)
Location
Africa (203)
Alabama (65)
Alaska (2)
Arizona (72)
Arkansas (5)
Asia (19311)
Australia (3262)
California (7220)
Canada (1921)
China (799)
Colorado (253)
Connecticut (263)
Delaware (241)
Europe (41907)
Florida (938)
Georgia (217)
Hawaii (2)
Idaho (17)
Illinois (430)
India (37)
Indiana (172)
Iowa (10)
Japan (237)
Kansas (81)
Kentucky (9)
Louisiana (12)
Maine (16)
Maryland (754)
Massachusetts (5678)
Michigan (118)
Minnesota (253)
Mississippi (3)
Missouri (35)
Montana (16)
Nebraska (5)
Nevada (36)
New Hampshire (24)
New Jersey (1699)
New Mexico (14)
New York (1817)
North Carolina (844)
North Dakota (6)
Northern California (3555)
Ohio (185)
Oklahoma (11)
Oregon (24)
Pennsylvania (1306)
Puerto Rico (10)
Rhode Island (27)
South America (264)
South Carolina (10)
Southern California (2861)
Tennessee (42)
Texas (939)
United States (23944)
Utah (103)
Virginia (144)
Washington D.C. (41)
Washington State (608)
West Virginia (1)
Wisconsin (47)
306,673 Results for "rise therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Artificial intelligence
AI-Enabled Clinical Improvements Confirm Biotech Hype as Success Rates Rise
As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: speeding drug development.
January 21, 2026
·
3 min read
·
Annalee Armstrong
GLP-1
A Compounding Problem: How GLP-1s Drove Novo Nordisk’s Rapid Rise and Fall
Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma recover?
August 13, 2025
·
5 min read
·
Nick Paul Taylor
Obesity
Novo Rises as Oral Wegovy Reaches Over 3,000 Patients in First Week of Launch
Despite ushering in the current GLP-1 era, Novo Nordisk has fallen behind its chief rival Eli Lilly, which has exceeded the Danish pharma in terms of sales.
January 19, 2026
·
1 min read
·
Tristan Manalac
Press Releases
Tuberculosis Therapeutics Market to Hit USD 2.11 Billion in 2025 on Rising Disease Burden
September 22, 2025
·
1 min read
Press Releases
LUNGevity and Rising Tide Foundation Issue RFA Tackling Lung Cancer’s Toughest Challenges: Drug Resistance and Cancer Recurrence
January 16, 2026
·
5 min read
Press Releases
Myocardial Ischemia Market to Reach US$ 7.98 Billion by 2032, Driven by Rising Cardiovascular Disease Burden
January 13, 2026
·
1 min read
Press Releases
Meloxicam Market Surpassed USD 12.34 Billion in 2032 Amid Rising Arthritis and Chronic Pain Cases
January 13, 2026
·
1 min read
Press Releases
Why Is Demand for Clinical Trials Market Rising Rapidly Across the U.S.?
December 4, 2025
·
1 min read
Press Releases
Brugada Syndrome Market Size to Exceed USD 2.08 Billion by 2032 on Rising Awareness and Early Diagnosis | Coherent Market Insights
January 16, 2026
·
1 min read
Alzheimer’s disease
Biogen’s Leqembi Rises After Novo GLP-1 Fails in Alzheimer’s
Analysts agree that the failure of Novo Nordisk’s semaglutide to reduce Alzheimer’s disease progression removes a “modest” or “perceived” overhang on Biogen and the anti-amyloid antibody class in general, clearing the way for increased uptake of Leqembi and Eli Lilly’s Kisunla.
November 24, 2025
·
3 min read
·
Heather McKenzie
1 of 30,668
Next
